Dexlansoprazole (BioDeep_00000834650)
代谢物信息卡片
Dexlansoprazole
化学式: C16H14F3N3O2S (369.07587800000005)
中文名称: 右旋兰索拉唑
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
InChI: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
描述信息
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor
D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors
(R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
同义名列表
2 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:135931
- KEGGdrug: D08903
- PubChem: 9578005
- DrugBank: DB05351
- ChEMBL: CHEMBL1201863
- MeSH: Dexlansoprazole
- CAS: 138530-94-6
- RefMet: Dexlansoprazole
- medchemexpress: HY-13662B
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Noha Mahmoud Elkhodary, Khaled Abdalkader Farrag, Amany Mahmoud Elokaby, Gamal Abd El-Hay Omran. Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of Helicobacter pylori: A pilot randomized trial.
Indian journal of pharmacology.
2020 Sep; 52(5):356-364. doi:
10.4103/ijp.ijp_364_19. [PMID: 33283766] - Haiyan Grady, Yusuke Murakawa, Darcy Mulford, Michael Kukulka. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
Journal of pharmaceutical sciences.
2019 11; 108(11):3496-3501. doi:
10.1016/j.xphs.2019.07.023. [PMID: 31386865] - Lihua Wu, Jian Liu, Yunliang Zheng, You Zhai, Meihua Lin, Guolan Wu, Duo Lv, Jianzhong Shentu. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Clinical drug investigation.
2019 Oct; 39(10):953-965. doi:
10.1007/s40261-019-00824-2. [PMID: 31338800] - Karen E Hansen, Jeri W Nieves, Sai Nudurupati, David C Metz, Maria Claudia Perez. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.
Gastroenterology.
2019 03; 156(4):926-934.e6. doi:
10.1053/j.gastro.2018.11.023. [PMID: 30445008] - Biljana Jovov, Craig C Reed, Nicholas J Shaheen, Amy Pruitt, Kathleen Ferrell, Geraldine S Orlando, Zorka Djukic, Roy C Orlando. Fragments of e-Cadherin as Biomarkers of Non-erosive Reflux Disease.
Digestive diseases and sciences.
2018 03; 63(3):628-635. doi:
10.1007/s10620-017-4815-4. [PMID: 29071486] - S Tommasi, D J Elliot, J A Hulin, B C Lewis, M McEvoy, A A Mangoni. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance.
Scientific reports.
2017 06; 7(1):2871. doi:
10.1038/s41598-017-03069-1. [PMID: 28588208] - Yue-Qi Li, Zheng-Yu Yan, Hong-Wen Zhang, Lu-Ning Sun, Hui-Wen Jiao, Mei-Feng Wang, Li-Yuan Yu, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Yong-Qing Wang. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
European journal of clinical pharmacology.
2017 May; 73(5):547-554. doi:
10.1007/s00228-017-2206-6. [PMID: 28138748] - Zhang Dawei, He Hongqiu, Liu Mengmeng, Meng Zhixia, Guo Shunxing. A Novel Assay for Screening Inhibitors Targeting HIV Integrase LEDGF/p75 Interaction Based on Ni(2+) Coated Magnetic Agarose Beads.
Scientific reports.
2016 09; 6(?):33477. doi:
10.1038/srep33477. [PMID: 27633629] - Barbara Skrzydło-Radomańska, Piotr Radwan. Dexlansoprazole - a new-generation proton pump inhibitor.
Przeglad gastroenterologiczny.
2015; 10(4):191-6. doi:
10.5114/pg.2015.56109. [PMID: 26759624] - Jeanetta W Frye, David A Peura. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.
Therapeutics and clinical risk management.
2015; 11(?):1649-56. doi:
10.2147/tcrm.s66680. [PMID: 26586949] - Yohannes T Ghebremariam, Paea LePendu, Jerry C Lee, Daniel A Erlanson, Anna Slaviero, Nigam H Shah, James Leiper, John P Cooke. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.
Circulation.
2013 Aug; 128(8):845-53. doi:
10.1161/circulationaha.113.003602. [PMID: 23825361] - Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, Zheng Yang, Ragini Vuppugalla, Jeremy Hurley, Denise Thorndike, Andrew Wagner, Anjaneya Chimalakonda, A David Rodrigues. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Sep; 40(9):1698-711. doi:
10.1124/dmd.112.045575. [PMID: 22648560] - Brian Grabowski, Ronald D Lee. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
Clinical drug investigation.
2012 May; 32(5):319-32. doi:
10.2165/11630930-000000000-00000. [PMID: 22455762] - Andrew L Frelinger, Ronald D Lee, Darcy J Mulford, Jingtao Wu, Sai Nudurupati, Anu Nigam, Julie K Brooks, Deepak L Bhatt, Alan D Michelson. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Journal of the American College of Cardiology.
2012 Apr; 59(14):1304-11. doi:
10.1016/j.jacc.2011.12.024. [PMID: 22464259] - Kishore Kumar Hotha, D Vijaya Bharathi, B Jagadeesh, L K Ravindranath, K N Jaya Veera, V Venkateswarulu. Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study.
Biomedical chromatography : BMC.
2012 Feb; 26(2):192-8. doi:
10.1002/bmc.1645. [PMID: 21618562] - Michael Kukulka, Jingtao Wu, Maria Claudia Perez. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
Journal of pediatric gastroenterology and nutrition.
2012 Jan; 54(1):41-7. doi:
10.1097/mpg.0b013e31822a323a. [PMID: 21716130] - Brian W Behm, David A Peura. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Expert review of gastroenterology & hepatology.
2011 Aug; 5(4):439-45. doi:
10.1586/egh.11.37. [PMID: 21780890] - A H Dabholkar, C Han, M M Paris, M C Perez, S N Atkinson, D A Peura. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Alimentary pharmacology & therapeutics.
2011 Feb; 33(3):366-77. doi:
10.1111/j.1365-2036.2010.04519.x. [PMID: 21118280] - Majid Vakily, Jingtao Wu, Stuart N Atkinson. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
Journal of clinical pharmacology.
2009 Dec; 49(12):1447-55. doi:
10.1177/0091270009339188. [PMID: 19826060] - D A Peura, D C Metz, A H Dabholkar, M M Paris, P Yu, S N Atkinson. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Alimentary pharmacology & therapeutics.
2009 Nov; 30(10):1010-21. doi:
10.1111/j.1365-2036.2009.04137.x. [PMID: 19735233] - D C Metz, M Vakily, T Dixit, D Mulford. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Alimentary pharmacology & therapeutics.
2009 May; 29(9):928-37. doi:
10.1111/j.1365-2036.2009.03984.x. [PMID: 19298580] - R D Lee, M Vakily, D Mulford, J Wu, S N Atkinson. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Alimentary pharmacology & therapeutics.
2009 Apr; 29(8):824-33. doi:
10.1111/j.1365-2036.2009.03979.x. [PMID: 19243357] - Weijiang Zhang, Jingtao Wu, Stuart N Atkinson. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
Journal of clinical pharmacology.
2009 Apr; 49(4):444-54. doi:
10.1177/0091270008330155. [PMID: 19318694] - Majid Vakily, Weijiang Zhang, Jingtao Wu, Stuart N Atkinson, Darcy Mulford. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Current medical research and opinion.
2009 Mar; 25(3):627-38. doi:
10.1185/03007990802693883. [PMID: 19232037] - Eric T Wittbrodt, Charles Baum, David A Peura. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Clinical and experimental gastroenterology.
2009; 2(?):117-28. doi:
10.2147/ceg.s5765. [PMID: 21694835] - Majid Vakily, Ronald D Lee, Jingtao Wu, Lhanoo Gunawardhana, Darcy Mulford. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Clinical drug investigation.
2009; 29(1):35-50. doi:
10.2165/0044011-200929010-00004. [PMID: 19067473] - Takenori Niioka, Masatomo Miura, Tsukasa Uno, Norio Yasui-Furukori, Makoto Hayakari, Tomonori Tateishi, Toshio Suzuki. Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
European journal of clinical pharmacology.
2008 May; 64(5):503-9. doi:
10.1007/s00228-007-0455-5. [PMID: 18224311] - M Miura, S Satoh, H Tada, M Saito, H Kagaya, K Inoue, Y Sagae, S Kanno, M Ishikawa, T Habuchi, T Suzuki. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
International journal of clinical pharmacology and therapeutics.
2006 Dec; 44(12):605-13. doi:
10.5414/cpp44605. [PMID: 17190370] - Masatomo Miura. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
2006 Jun; 126(6):395-402. doi:
10.1248/yakushi.126.395. [PMID: 16755125] - M Miura, H Kagaya, H Tada, T Uno, N Yasui-Furukori, T Tateishi, T Suzuki. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
Xenobiotica; the fate of foreign compounds in biological systems.
2006 Jan; 36(1):95-102. doi:
10.1080/00498250500485065. [PMID: 16507515] - Masatomo Miura, Hitoshi Tada, Norio Yasui-Furukori, Tsukasa Uno, Kazunobu Sugawara, Tomonori Tateishi, Toshio Suzuki. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
British journal of clinical pharmacology.
2005 Jul; 60(1):61-8. doi:
10.1111/j.1365-2125.2005.02381.x. [PMID: 15963095] - M Miura, H Kagaya, H Tada, Y Sagae, S Satoh, T Habuchi, T Suzuki. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Xenobiotica; the fate of foreign compounds in biological systems.
2005 May; 35(5):479-86. doi:
10.1080/00498250500111562. [PMID: 16012079] - M Miura, H Tada, N Yasui-Furukori, T Uno, K Sugawara, T Tateishi, T Suzuki. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
European journal of clinical pharmacology.
2004 Nov; 60(9):623-8. doi:
10.1007/s00228-004-0809-1. [PMID: 15448955] - Kyoung-Ah Kim, Ji-Hong Shon, Ji-Young Park, Young-Ran Yoon, Min-Jung Kim, Doo-Hee Yun, Moon-Kyung Kim, In-June Cha, Myung-Ho Hyun, Jae-Gook Shin. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Clinical pharmacology and therapeutics.
2002 Jul; 72(1):90-9. doi:
10.1067/mcp.2002.126176. [PMID: 12152007]